Sarecycline HCl

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 319682

CAS#: 1035979-44-2 (HCl)

Description: Sarecycline, also known as WC-3035 and P005672, is a novel, tetracycline-derived, narrow-spectrum antibiotic being developed for use as an oral once daily antibiotic treatment for patients suffering from moderate to severe acne vulgaris. Sarecycline was designed by Paratek as a narrow-spectrum antibiotic with anti-inflammatory activity and the potential for a favorable tolerability profile.

Chemical Structure

Sarecycline HCl
CAS# 1035979-44-2 (HCl)

Theoretical Analysis

MedKoo Cat#: 319682
Name: Sarecycline HCl
CAS#: 1035979-44-2 (HCl)
Chemical Formula: C24H30ClN3O8
Exact Mass:
Molecular Weight: 523.967
Elemental Analysis: C, 55.02; H, 5.77; Cl, 6.77; N, 8.02; O, 24.43

Price and Availability

Size Price Availability Quantity
5.0mg USD 350.0 2 Weeks
Bulk inquiry

Related CAS #: 1035979-44-2 (HCl)   1035654-66-0 (free base)    

Synonym: WC-3035; WC 3035; WC3035; P005672; P-005672; P 005672; P005672 HCl; Sarecycline hydrochloride; Seysara

IUPAC/Chemical Name: (4S,4aS,5aR,12aS)-4-(dimethylamino)-3,10,12,12a-tetrahydroxy-7-((methoxy(methyl)amino)methyl)-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide hydrochloride


InChi Code: InChI=1S/C24H29N3O8.ClH/c1-26(2)18-13-8-11-7-12-10(9-27(3)35-4)5-6-14(28)16(12)19(29)15(11)21(31)24(13,34)22(32)17(20(18)30)23(25)33;/h5-6,11,13,18,28,30-31,34H,7-9H2,1-4H3,(H2,25,33);1H/t11-,13-,18-,24-;/m0./s1

SMILES Code: O=C(C1=C(O)[C@@H](N(C)C)[C@@](C[C@@]2([H])C(C(C3=C(O)C=CC(CN(OC)C)=C3C2)=O)=C4O)([H])[C@@]4(O)C1=O)N.[H]Cl

Appearance: Solid powder

Purity: >95% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 523.967 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

1: Kaul G, Saxena D, Dasgupta A, Chopra S. Sarecycline hydrochloride for the treatment of acne vulgaris. Drugs Today (Barc). 2019 Oct;55(10):615-625. doi: 10.1358/dot.2019.55.10.3045040. Review. PubMed PMID: 31720559.

2: LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. Available from PubMed PMID: 31643616.

3: Hussar DA, Chahine EB. Omadacycline tosylate, Sarecycline hydrochloride, Rifamycin sodium, and Moxidectin. J Am Pharm Assoc (2003). 2019 Sep - Oct;59(5):756-760. doi: 10.1016/j.japh.2019.07.016. PubMed PMID: 31522740.

4: Moore AY, Charles JEM, Moore S. Sarecycline: a narrow spectrum tetracycline for the treatment of moderate-to-severe acne vulgaris. Future Microbiol. 2019 Sep;14:1235-1242. doi: 10.2217/fmb-2019-0199. Epub 2019 Sep 2. PubMed PMID: 31475868; PubMed Central PMCID: PMC6802708.

5: Haidari W, Bruinsma R, Cardenas-de la Garza JA, Feldman SR. Sarecycline Review. Ann Pharmacother. 2019 Aug 28:1060028019873111. doi: 10.1177/1060028019873111. [Epub ahead of print] PubMed PMID: 31462063.

6: Deeks ED. Correction to: Sarecycline: First Global Approval. Drugs. 2019 May;79(7):795. doi: 10.1007/s40265-019-01122-z. PubMed PMID: 31037601; PubMed Central PMCID: PMC6520308.

7: Sarecycline (Seysara) - another oral tetracycline for acne. Med Lett Drugs Ther. 2019 Mar 25;61(1568):43-44. Review. PubMed PMID: 31022156.

8: Deeks ED. Sarecycline: First Global Approval. Drugs. 2019 Feb;79(3):325-329. doi: 10.1007/s40265-019-1053-4. Review. Erratum in: Drugs. 2019 Apr 29;:. PubMed PMID: 30659422; PubMed Central PMCID: PMC6505496.

9: Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006-. Available from PubMed PMID: 30601614.

10: Zhanel G, Critchley I, Lin LY, Alvandi N. Microbiological Profile of Sarecycline, a Novel Targeted Spectrum Tetracycline for the Treatment of Acne Vulgaris. Antimicrob Agents Chemother. 2018 Dec 21;63(1). pii: e01297-18. doi: 10.1128/AAC.01297-18. Print 2019 Jan. PubMed PMID: 30397052; PubMed Central PMCID: PMC6325184.

11: Moore A, Green LJ, Bruce S, Sadick N, Tschen E, Werschler P, Cook-Bolden FE, Dhawan SS, Forsha D, Gold MH, Guenthner S, Kempers SE, Kircik LH, Parish JL, Rendon MI, Rich P, Stein-Gold L, Tyring SK, Weiss RA, Nasir A, Schmitz C, Boodhoo TI, Kaoukhov A, Berk DR. Once-Daily Oral Sarecycline 1.5 mg/kg/day Is Effective for Moderate to Severe Acne Vulgaris: Results from Two Identically Designed, Phase 3, Randomized, Double-Blind Clinical Trials. J Drugs Dermatol. 2018 Sep 1;17(9):987-996. PubMed PMID: 30235387.

12: Leyden JJ, Sniukiene V, Berk DR, Kaoukhov A. Efficacy and Safety of Sarecycline, a Novel, Once-Daily, Narrow Spectrum Antibiotic for the Treatment of Moderate to Severe Facial Acne Vulgaris: Results of a Phase 2, Dose-Ranging Study. J Drugs Dermatol. 2018 Mar 1;17(3):333-338. PubMed PMID: 29537451.